Skip to main content

Advertisement

Log in

Influence of UGT genetic polymorphism on the interindividual variability in mitiglinide pharmacokinetic in Chinese

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

The aim of the study is to identify the effect of UDP-glucuronosyltransferase (UGT) genetic polymorphism on the interindividual variability in mitiglinide pharmacokinetics (PK) in Chinese. PK and genetic data were obtained from 42 healthy Chinese volunteers (Han ethnic group) treated with single-dose and multiple-dose oral mitiglinide using liquid chromatography/mass spectrometry and DNA sequencing technologies. And the result showed there were great interindividual variabilities in main PK parameters (AUC, Cmax and CL/F) for multiple oral mitiglinide. The enzyme activity of the carriers of UGT1A3 *2/*4 or UGT2B7-1 T/T was stronger than that of the carriers of other genotypes. These results demonstrate that UGT1A3 and UGT2B7-1 genetic polymorphism may have a significant impact on interindividual variability in the PK of mitiglinide in Chinese.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

AUC:

The area under curve

C max :

Maximum concentration

CL/F:

Clearance

MGN:

Mitiglinide

PK:

Pharmacokinetics

UGT:

Uridine 5′-diphospho-glucuronosyltransferase

References

  • Awewura K, Margaret L, Isaac B, Naser LR, Joseph OC, Ernest K, Angela DMK, Michael H (2009) Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in tb/hiv co-infected Ghanaian patients: UGT2B7*1C is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 49:1079–1090

    Article  Google Scholar 

  • Bhasker CR, McKinnon W, Stone AN, Lo AC, Kubota T, Ishizaki T, Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679–685

    Article  PubMed  CAS  Google Scholar 

  • Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1–4

    PubMed  CAS  Google Scholar 

  • Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7 Y (268) and UGT2B7 H (268). Drug Metab Dispos 26:73–77

    PubMed  CAS  Google Scholar 

  • Federico I, Wanqing L, Donna F, Jacqueline R, PeiXian C, Xin Ye, Xiaolin W, Wei Z, Snezana M, Soma D, Edwin C, Mark JR (2008) SNP discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene. Pharmacogenet Genomics 18:683–697

    Article  Google Scholar 

  • Girard C, Barbier O, Veilleux G, El-Alfy M, Bélanger A (2003) Human uridine diphosphate glucuronosyl transferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology 144:2659–2668

    Article  PubMed  CAS  Google Scholar 

  • Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475–479

    PubMed  CAS  Google Scholar 

  • John OM, Ross AM, Peter IM (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181–182:453–456

    Google Scholar 

  • Mojarrabi B, Butler R, Mackenzie PI (1996) cDNA cloning and characterization of the human UDP glucuronosyltransferase UGT1A3. Biochem Biophys Res Commun 225:785–790

    Article  PubMed  CAS  Google Scholar 

  • Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F (1994) Novel rapid-and short-acting hypoglycemic agent, a calcium-(2 s)-2-benzyl-3-(cishexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and glicalzide. J Pharmacol Exp Ther 269:489–495

    PubMed  CAS  Google Scholar 

  • Ojima K, Kiyono Y, Kojima M (2004) Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset. Nippon Yakurigaku Zasshi 124:245–255

    Article  PubMed  CAS  Google Scholar 

  • Yasuhiro S, Tohru G, Tadao S, Kiyoshi I, Hiroshi K, Hideki Y, Susumu S (2001) The effects of mitiglinide KAD1229, a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 431:119–125

    Article  Google Scholar 

  • Yu L, Lu S, Lin Y, Su Z (2007) Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyl transferases. Biochem Pharmacol 73:1842–1851

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhan-qing Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, Jf., Wang, Zq., Yan, Cx. et al. Influence of UGT genetic polymorphism on the interindividual variability in mitiglinide pharmacokinetic in Chinese. Med Chem Res 21, 2595–2602 (2012). https://doi.org/10.1007/s00044-011-9784-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-011-9784-0

Keywords

Navigation